FRIDAY, Oct. 16, 2020 — Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDS), according to a study published online Oct. 15 in the New England Journal of Medicine. Andrea Rubbert-Roth, M.D.,…